January 2000 in “Time to knit” Emulgels are promising for delivering drugs topically due to their easy spreadability and stability.
16 citations
,
January 2020 in “Annals of the rheumatic diseases” Baricitinib might help treat hair loss in lupus patients, but more research is needed.
March 2026 in “Journal of the American Academy of Dermatology” 58 citations
,
September 2019 in “EMBO Molecular Medicine” CDK4/6 inhibitors can protect hair cells from chemotherapy damage.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
December 2015 in “OPAL (Open@LaTrobe) (La Trobe University)” QLT0267 stops hair follicle cell growth and movement.
22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
118 citations
,
April 2020 in “Stem Cell Research & Therapy” IFNγ-primed MSC secretomes can improve joint health by reducing inflammation and supporting tissue repair.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
February 2026 in “Frontiers in Medicine” Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.
October 2025 in “Transactions on Materials Biotechnology and Life Sciences” Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.
10 citations
,
August 2016 in “Oxford Medical Case Reports” Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
September 2022 in “Journal of Ayub Medical College Abbottabad” Steroid injections are more effective than platelet rich plasma for treating patchy hair loss.
12 citations
,
April 2023 in “Molecular Pharmaceutics” A new patch can deliver stable antibodies over time for potential HIV treatment.
June 2020 in “Annals of the Rheumatic Diseases” Patients need better information about the risks of long-term steroid use.
3 citations
,
August 2024 in “British Journal of Dermatology” Dupilumab may help treat hair loss and skin color loss in some patients with atopic dermatitis.
April 2019 in “Institutional Repositories DataBase (IRDB)” Patient-derived stem cell melanocytes could be a promising treatment for vitiligo.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
184 citations
,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
IP-PA1 helps grow hair in mice and affects human cell growth-related genes differently than traditional hair growth treatments.
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
October 2025 in “The American Journal of Gastroenterology” Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.
Dexamethasone-primed stem cell media shows promise in treating lupus by reducing symptoms and inflammation.
53 citations
,
September 2020 in “Stem Cell Research & Therapy” New methods to improve the healing abilities of mesenchymal stem cells for disease treatment are promising but need more research.